Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) ...
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
The TALAPRO-2 study showed a median overall survival of 45.8 months for the combination therapy versus 37.0 months for the control group. Radiographic progression-free survival was notably improved ...
Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower ...
Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP ...
Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback